Trial · NCT02818309
Lesogaberan in Chinese Patients With Refractory Reflux Symptoms
NCT02818309, Phase 2, Unknown, National Taiwan University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Lesogaberan in Chinese Patients With Refractory Reflux Symptoms. Trials, record NCT02818309. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02818309
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Lesogaberan in Chinese Patients With Refractory Reflux Symptoms
- NCT number
- NCT02818309
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 72 participants, estimated
- Lead sponsor
- National Taiwan University Hospital
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- Lesogaberan, Placebo
- First posted
- 2016-06-29
- Last updated
- 2016-06-29
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment response as assessed by the symptom questionnaire RESQ-eD | 3 years | Treatment response, defined as at most three days with heartburn or regurgitation of not more than mild intensity during the last 7 days of treatment based on RESQ-eD |
| Secondary | Time to treatment response as assessed by the symptom questionnaire RESQ-eD | 3 years | time from the day of the first dose to the first of seven consecutive days meeting the responder definition |
| Secondary | Time to sustained absence of symptoms as assessed by the symptom questionnaire RESQ-eD | 3 years | time from the day of the first dose to the first of seven consecutive symptom-free days |
| Secondary | The proportion of symptom-free days as assessed by the symptom questionnaire RESQ-eD | 3 years | |
| Secondary | The change from baseline for each separate symptom domain of the RESQ-eD | 3 years | |
| Secondary | Patients' consumption of rescue antacid medication over the 4 week treatment period | 3 years | |
| Secondary | Patient compliance with treatment determined by counts of returned unused capsules at each visit during the period of randomised treatment | 3 years | |
| Secondary | Subgroup analysis of in patients with different reflux profiles categorized by impedance-pH as assessed by the symptom questionnaire RESQ-eD | 3 years | Treatment response, defined as at most three days with heartburn or regurgitation of not more than mild intensity during the last 7 days of treatment based on RESQ-eD |
| Secondary | Number of participants with treatment-related adverse events as assessed by CRF_20150728 | 3 years | Adverse events are any untoward medical occurrences in a patient or clinical trial subject to whom a medicinal product has been administered including occurrences which are not necessarily caused by or related to that product. According to previous studies, the common adverse events of lesogaberan include paraesthesia, diarrhea, pruritus, dizziness and nausea. The serious adverse events are defined as following: 1. results in death; 2. life-threatening; 3. requires hospitalisation or prolongation of existing hospitalisation; 4. results in persistent or significant disability or incapacity |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02818309
GET https://conductscience.org/api/trials/v1/NCT02818309/registered